CN103533833B - 降脂抗糖尿病剂 - Google Patents

降脂抗糖尿病剂 Download PDF

Info

Publication number
CN103533833B
CN103533833B CN201280005222.1A CN201280005222A CN103533833B CN 103533833 B CN103533833 B CN 103533833B CN 201280005222 A CN201280005222 A CN 201280005222A CN 103533833 B CN103533833 B CN 103533833B
Authority
CN
China
Prior art keywords
metformin
diabetes
experimenter
acid
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280005222.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103533833A (zh
Inventor
B·L·迈拉里
F·C·夏沃利诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Publication of CN103533833A publication Critical patent/CN103533833A/zh
Application granted granted Critical
Publication of CN103533833B publication Critical patent/CN103533833B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/52—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing groups, e.g. carboxylic acid amidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/06—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C07C251/08—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton being acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Endocrinology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280005222.1A 2011-01-12 2012-01-12 降脂抗糖尿病剂 Expired - Fee Related CN103533833B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161461113P 2011-01-12 2011-01-12
US61/461,113 2011-01-12
US13/348,265 2012-01-11
US13/348,265 US20120178813A1 (en) 2011-01-12 2012-01-11 Lipid-lowering antidiabetic agent
PCT/US2012/021070 WO2012097144A1 (en) 2011-01-12 2012-01-12 Lipid-lowering antidiabetic agent

Publications (2)

Publication Number Publication Date
CN103533833A CN103533833A (zh) 2014-01-22
CN103533833B true CN103533833B (zh) 2016-08-31

Family

ID=46455756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280005222.1A Expired - Fee Related CN103533833B (zh) 2011-01-12 2012-01-12 降脂抗糖尿病剂

Country Status (12)

Country Link
US (4) US20120178813A1 (enExample)
EP (1) EP2663186A4 (enExample)
JP (1) JP5911514B2 (enExample)
KR (1) KR20140092228A (enExample)
CN (1) CN103533833B (enExample)
AU (1) AU2012205547B2 (enExample)
BR (1) BR112013017845A2 (enExample)
CA (1) CA2824192A1 (enExample)
EA (1) EA201391028A1 (enExample)
IL (1) IL227346A0 (enExample)
MX (1) MX2013008131A (enExample)
WO (1) WO2012097144A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
BR112015000368A2 (pt) * 2012-07-10 2017-06-27 Thetis Pharmaceuticals Llc forma de tri-sais de metformina
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014080307A2 (en) * 2012-11-21 2014-05-30 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014195810A2 (en) * 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
SG11201509782TA (en) * 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015171516A1 (en) * 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016132186A1 (en) * 2015-02-20 2016-08-25 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2016151372A1 (en) * 2015-03-21 2016-09-29 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
KR102628351B1 (ko) 2017-08-15 2024-01-25 에보니크 오퍼레이션즈 게엠베하 오메가-3 지방산 아미노산 염의 높은 활성 성분 함량을 갖는 정제
US11497722B2 (en) * 2017-12-18 2022-11-15 Soochow University Use of metformin salt in the treatment of cerebral infarction
KR102977459B1 (ko) 2019-08-08 2026-06-16 에보니크 오퍼레이션즈 게엠베하 다중불포화 지방산 염의 제조를 위한 다운스트림 공정
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
CN113105367B (zh) 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN115192625A (zh) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 一种口服组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077335A1 (en) * 2000-11-03 2003-04-24 Chronorx Llc Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20050182029A1 (en) * 2002-02-14 2005-08-18 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
CN1761405A (zh) * 2003-03-18 2006-04-19 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CN1416341B (zh) 2000-02-04 2010-05-05 武田药品工业株式会社 稳定的乳液组合物
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818906B1 (fr) * 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
JP4220247B2 (ja) 2001-03-29 2009-02-04 ビーエーエスエフ ソシエタス・ヨーロピア 共役不飽和グリセリド混合物及びその製造方法
JP4744081B2 (ja) 2001-08-31 2011-08-10 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 植物抽出物を用いて障害を処置するための方法
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP1558237A4 (en) * 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED BLOOD SUGAR CONTROL F RPRU-DIABETES AND / OR DIABETES TYPE II USING DOCOSAHEXAENSURE
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CA2543722C (en) 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
RU2006118801A (ru) * 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
EP1708707A1 (en) 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
US20060003976A1 (en) 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
US20100021555A1 (en) * 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
EP1804815A2 (en) 2004-10-29 2007-07-11 Joan Campell-Tofte Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same
EP1898922A4 (en) 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
EP1960356A2 (en) 2005-11-03 2008-08-27 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
AU2007213506A1 (en) * 2006-02-07 2007-08-16 Universitetet I Oslo Omega 3
EP1984355A2 (en) 2006-02-16 2008-10-29 Takeda Pharmaceutical Company Limited Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
CN101522658A (zh) 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
US8399516B2 (en) 2006-11-01 2013-03-19 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR)
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
WO2008058274A2 (en) * 2006-11-09 2008-05-15 Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
WO2008093984A1 (en) * 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
TW200904433A (en) 2007-04-27 2009-02-01 Takeda Pharmaceutical Substituted imidazole compound and use thereof
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー，リミテッド Ｎ，ｎ−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
SG188117A1 (en) 2008-06-19 2013-03-28 Takeda Pharmaceutical Heterocyclic compound and use thereof
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077335A1 (en) * 2000-11-03 2003-04-24 Chronorx Llc Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US20050182029A1 (en) * 2002-02-14 2005-08-18 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
CN1761405A (zh) * 2003-03-18 2006-04-19 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
WO2010127099A2 (en) * 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Also Published As

Publication number Publication date
CN103533833A (zh) 2014-01-22
US20130281535A1 (en) 2013-10-24
JP5911514B2 (ja) 2016-04-27
EA201391028A1 (ru) 2013-12-30
AU2012205547A1 (en) 2013-08-01
IL227346A0 (en) 2013-09-30
US9012507B2 (en) 2015-04-21
US9216951B2 (en) 2015-12-22
US20150051284A1 (en) 2015-02-19
BR112013017845A2 (pt) 2019-09-24
EP2663186A4 (en) 2014-09-24
WO2012097144A1 (en) 2012-07-19
MX2013008131A (es) 2014-01-08
JP2014512333A (ja) 2014-05-22
US20120178813A1 (en) 2012-07-12
AU2012205547B2 (en) 2015-08-27
US8901107B2 (en) 2014-12-02
EP2663186A1 (en) 2013-11-20
US20140107360A1 (en) 2014-04-17
KR20140092228A (ko) 2014-07-23
CA2824192A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
US9012507B2 (en) Lipid-lowering antidiabetic agent
US7973073B2 (en) Antidiabetic agent for control of diabetic hyperglycemia and diabetic complications
US20220249463A1 (en) Methods of altering cardiac remodeling using compounds that promote glucose oxidation
WO2003068209A1 (en) Metformin salts of lipophilic acids
US8933124B2 (en) Tri-salt form of metformin
US8853259B2 (en) Metformin derivatives for treating diabetes and diabetes complications
WO2014011814A1 (en) Tri-salt form of metformin
US20140024708A1 (en) Ursolic acid salts for treating diabetes and obesity
TW516959B (en) Composition containing ascorbic acid
WO2014008374A2 (en) Combination therapies comprising metformin salts and antihyperglycemia agents or antihyperlipidemia agents
US8440723B2 (en) Metformin salts of salicylic acid and its congeners
US9382187B2 (en) Tri-salt form of metformin
CN100486960C (zh) 双胍类衍生物及其制备方法
HK1137446A (en) Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160831

Termination date: 20170112